Bioprinting companies focus on creating living tissues for medical applications, offering innovative solutions in regenerative medicine. These firms utilize cutting-edge 3D printing technology to develop products such as customized organ models, bioinks, and more. The industry is expanding rapidly, fueled by advancements in biotechnology and an increasing demand for personalized healthcare. Many companies are collaborating with research institutions and industry leaders, indicating a trend toward integrated approaches in healthcare solutions. As the technology matures, bioprinting is poised to redefine therapeutic methods, paving the way for breakthroughs in organ transplantation and disease treatment.

This list features 28 bioprinting companies spanning various sizes, from startups to established firms. They are headquartered in countries like the USA, Canada, India, and more, and were founded between 2001 and 2024. Specializations range from advanced bioprinters and bioinks to tissue engineering solutions. Companies employ between 1 and 200 employees, representing a mix of private, venture capital, and corporate ownership models. Noteworthy examples include Aspect Biosystems, known for bioprinted tissue therapeutics, and Foldink, which provides customizable bioprinting solutions.

Continue reading to learn more about the top bioprinting companies.

Top 28 Bioprinting Companies Companies

1. Aspect Biosystems

• Website: aspectbiosystems.com
• Ownership type: Venture Capital
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: Series B, $115.0M, January 2025
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: aspect-biosystems

Aspect Biosystems, founded in 2013 and based in Vancouver, British Columbia, is a biotechnology firm that specializes in regenerative medicine and bioprinting technology. The company is dedicated to creating bioprinted tissue therapeutics aimed at addressing serious health issues, including type 1 diabetes and liver diseases. Their innovative approach combines proprietary bioprinting technology with therapeutic cells and biomaterials to develop allogeneic tissue therapeutics. Aspect Biosystems collaborates with pharmaceutical and biotech companies, leveraging strategic partnerships to enhance their therapeutic offerings. With a workforce of around 111 employees, the company has recently secured $115 million in Series B funding, underscoring its potential for growth and impact in the bioprinting industry.

2. Advanced Solutions Life Sciences

• Website: advancedsolutions.com
• Ownership type: Private
• Headquarters: Louisville, Kentucky, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: advanced-solutions-life-sciences

Advanced Solutions Life Sciences, founded in 2013 and based in Louisville, Kentucky, is a private biotechnology firm that specializes in 3D bioprinting and tissue engineering. The company is known for its innovative BioAssemblyBot, a sophisticated robotic system that allows for the creation of complex biological structures. This platform is not merely a 3D printer; it integrates advanced robotics with bioprinting capabilities, enabling the production of intricate tissue models and vascularization solutions. Their technology is utilized by researchers and developers in the pharmaceutical and medical industries, aiming to enhance drug discovery processes and tissue development. The company emphasizes a research-driven approach, focusing on high-quality bioprinting solutions that can replicate human tissues and support the development of new therapeutic strategies.

3. Next Big Innovation Labs

• Website: nextbiginnovationlabs.com
• Ownership type: Private
• Headquarters: Bengaluru, Karnataka, India
• Employee distribution: India 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: nextbiginnovationlabs

Next Big Innovation Labs, founded in 2016 and based in Bengaluru, Karnataka, India, is a private biotechnology firm that specializes in advanced bioprinting solutions. The company offers a range of bioprinters under the Trivima series, designed to cater to researchers and clinicians in tissue engineering and regenerative medicine. Their product lineup includes models such as the Trivima Mini, Basic, Advanced, and Pro, each tailored to different levels of research expertise and application needs. The company emphasizes customization and adaptability in its technology, allowing clients to meet specific project requirements. In addition to providing bioprinters, Next Big Innovation Labs also offers training programs to help users maximize the potential of their bioprinting technology. Their focus on innovation and support for the biotechnology and healthcare sectors positions them as a significant contributor to advancements in bioprinting.

4. Regemat 3d

• Website: regemat3d.com
• Ownership type: Private
• Headquarters: Granada, Andalusia, Spain
• Employee distribution: Spain 100%
• Latest funding: Crowdfunding, $563,000, March 2022
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: regemat3d

Regemat 3D, founded in 2015 and based in Granada, Spain, is a biotechnology firm that focuses on 3D bioprinting and regenerative medicine. The company offers a range of products including advanced bioprinters, bioreactors, and biomaterials tailored for researchers and pharmaceutical companies. Their technology enables the development of functional human tissues and innovative drug testing solutions. Regemat 3D emphasizes customization in their products, allowing clients to adapt the bioprinting systems to their specific research needs. The company has also engaged in various projects and collaborations, enhancing its presence in the bioprinting industry. In March 2022, Regemat 3D raised approximately €562,695 through crowdfunding, indicating strong market interest in their offerings.

5. Foldink

• Website: foldink.bio
• Ownership type: Private
• Headquarters: Frisco, Texas, United States (USA)
• Employee distribution: Armenia 62%, United States (USA) 38%
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: foldink

Foldink is a biotechnology company based in Frisco, Texas, founded in 2018 and officially incorporated in 2021. The company specializes in 3D bioprinting technology, offering a range of products including hydrogel and freeze-dried bioinks, as well as customizable bioprinting solutions. Their primary clientele consists of biomedical researchers and organizations focused on tissue engineering and regenerative medicine. Foldink aims to empower these professionals with innovative tools that advance scientific research. The company is staffed by a small team of experts, including founders with backgrounds in biomedical science and medicine, and is supported by a strategic advisory board. Foldink's mission is to push the boundaries of bioprinting technology, contributing to applications in regenerative medicine, drug discovery, and personalized medicine. Their focus on customization allows researchers to tailor bioinks to their specific needs, enhancing the potential for groundbreaking discoveries in the field.

6. Polbionica

• Website: polbionica.com
• Ownership type: Private
• Headquarters: Wilmington, Delaware, United States (USA)
• Employee distribution: Poland 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: polbionica

Polbionica is a biotechnology firm based in Wilmington, Delaware, founded in 2019. The company focuses on 3D bioprinting and innovative medical solutions, with a particular emphasis on developing a bionic pancreas. This fully functional organ, created from living cells, aims to produce insulin and glucagon effectively. Polbionica also provides advanced biotissues and laboratory equipment tailored for healthcare applications. Their clientele includes healthcare providers and research institutions that seek cutting-edge technologies for tissue engineering and regenerative medicine. The company has successfully completed preclinical tests for its bionic pancreas and is preparing for clinical trials, indicating a strong commitment to advancing medical technology and improving patient outcomes.

7. FluidForm Bio

• Website: fluidformbio.com
• Ownership type: Venture Capital
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: January 2022
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: fluidform

FluidForm Bio, founded in 2018 and based in Waltham, Massachusetts, is a biotechnology firm that focuses on 3D bioprinting technology aimed at creating living human tissue for various medical applications. The company has developed a proprietary platform known as FRESH™, which allows for the construction of complex tissue structures that mimic natural human tissue. This technology is particularly relevant for applications in cell therapy, tissue restoration, and drug development. FluidForm Bio collaborates with prominent pharmaceutical and biotech companies, enhancing their capabilities in drug discovery and regenerative medicine. Their team comprises experts from fields such as biomedical engineering, synthetic biology, and advanced materials science, which positions them well within the bioprinting industry. The company has not reported any recent funding, but their ongoing partnerships and innovative technology suggest a solid foundation for future growth.

8. VoxCell BioInnovation

• Website: voxcellbio.com
• Ownership type: Venture Capital
• Headquarters: Victoria, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: Seed, September 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: voxcellbio

VoxCell BioInnovation, founded in 2020 and based in Victoria, British Columbia, is a biotechnology firm focused on advancing drug discovery and tissue engineering. The company specializes in developing bioprinted tissue models and bioinks, which are crucial for enhancing the reliability of preclinical data in therapeutic development. Their product line includes universal bioinks and biopolymers designed to replicate the extracellular matrix of soft tissues, facilitating the creation of complex 3D structures that mimic human tissues. VoxCell's proprietary software also allows for the generation of customizable vascular structures, further enhancing the functionality of their bioprinted models. The company serves pharmaceutical companies and research institutions, aiming to accelerate the preclinical pathway for new therapeutics. With a small but dedicated team, VoxCell is making strides in the bioprinting industry, recognized for its innovative approach and potential impact on healthcare.

9. FluidForm

• Website: fluidform3d.com
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: fluidform

FluidForm Bio is a biotechnology firm based in Waltham, Massachusetts, founded in 2018. The company is dedicated to bioprinting living human tissue, utilizing their proprietary FRESH™ technology. This innovative platform enables the construction of tissues that incorporate cells and vasculature, which are essential for effective chronic disease treatment. FluidForm collaborates with prominent pharmaceutical and biotech companies to develop advanced cell therapies and tissue models, enhancing drug development processes and regenerative medicine. Their technology has been validated for producing high-quality tissue across various applications, showcasing their commitment to transforming medical treatments through bioprinting.

10. Avay Biosciences

• Website: avay.tech
• Ownership type: Venture Capital
• Headquarters: Bengaluru, Karnataka, India
• Employee distribution: India 100%
• Latest funding: Pre-seed, $270,000, November 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: avay-biosciences

Avay Biosciences, founded in 2017 and based in Bengaluru, Karnataka, India, is a biotechnology firm that specializes in advanced instruments for bioprinting and liquid handling systems. With a team of 11-50 employees, the company caters primarily to research institutions and healthcare organizations, providing solutions that enhance capabilities in tissue engineering and cell culture. Avay designs and manufactures a range of products, including their Mito Bioprinters, which are tailored for replicating tissue environments. They also offer liquid handling systems and various biomaterials, such as sterile hydrogels, to support cell growth in three-dimensional cultures. The company has received pre-seed funding of $270,000 in November 2021, which underscores its potential for growth and innovation in the bioprinting sector. Avay's commitment to quality engineering and customer support further enhances its position in the industry.

11. BioCloner Health

• Website: bioclonerhealth.com
• Ownership type: Private
• Headquarters: Warsaw, Masovian Voivodeship, Poland
• Employee distribution: Poland 100%
• Founded year: 2001
• Headcount: 11-50
• LinkedIn: 45stages-sp-z-o-o

BioCloner Health, based in Warsaw, Poland, is a private biomedical technology company founded in 2001. The firm specializes in 3D bioprinting and engineering services, focusing on innovative solutions for tissue engineering that cater to both medical and veterinary professionals. BioCloner Health has developed the BioCloner 1.0, a multifunctional 3D printer designed for producing absorbable implants and other complex structures. The company emphasizes research and development, offering services in rapid prototyping and CNC machining. Their mission is to enhance the quality of life and health for both humans and animals through the introduction of modern technologies in medical fields. With a dedicated team of experts, BioCloner Health is actively engaged in advancing bioprinting technology and has established a fully functional 3D bioprinting laboratory.

12. Rokit Healthcare

• Website: rokithealthcare.com
• Ownership type: Venture Capital
• Headquarters: Geumcheon, Seoul, South Korea
• Employee distribution: South Korea 100%
• Latest funding: $2.1M, May 2024
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: rokithealthcare

Rokit Healthcare, founded in 2012 and based in Geumcheon, Seoul, South Korea, is a biotechnology firm dedicated to advancing organ regeneration and tissue engineering. The company leverages cutting-edge 3D bioprinting technology to create innovative solutions aimed at treating chronic conditions, including diabetic foot ulcers and osteoarthritis. Their clientele primarily consists of healthcare providers and patients seeking advanced regenerative therapies. Rokit Healthcare is committed to research and development, focusing on enhancing healing outcomes and improving patient care. Recently, they secured funding of approximately $2,078,164 in May 2024, indicating ongoing investor interest in their innovative approaches and technologies.

13. TheWell Bioscience

• Website: thewellbio.com
• Ownership type: Private
• Headquarters: South Brunswick Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: April 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: thewell-bioscience

TheWell Bioscience Inc. is a biotechnology firm based in South Brunswick Township, New Jersey, founded in 2017. The company specializes in 3D cell culture and bioprinting solutions, offering a range of products that include xeno-free hydrogels, bioinks, and assay kits. These products are tailored for researchers in the biomedical field, supporting advancements in personalized medicine and cell therapy. TheWell Bioscience's innovative offerings, such as their VitroGel® hydrogel and VitroINK® bioinks, are designed to create realistic 3D environments for cell culture, which is crucial for effective research and development. The company has established itself as a player in the bioprinting industry by providing tools that enhance the capabilities of researchers and contribute to the evolution of bioprinting technologies.

14. Scire Science

• Website: scire.co.in
• Ownership type: Private
• Headquarters: Ernakulam, Kerala, India
• Employee distribution: India 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: scirescience

Scire Science, founded in 2016 and based in Ernakulam, Kerala, India, is a private research and development company specializing in medtech and biotech innovations. With a team of 21 employees, the company focuses on providing a range of services and products that cater to the life sciences and healthcare sectors. Scire Science is particularly noted for its work in 3D bioprinting and advanced cell culture techniques, which are pivotal in the development of personalized medicine and regenerative therapies. Their product offerings include biomaterials and bioinks, essential for bioprinting applications. The company also provides research services, training, and product development support, making it a key player in advancing healthcare solutions. Scire Science is dedicated to pushing the boundaries of scientific research and innovation, contributing to the evolution of healthcare technologies.

15. Carcinotech Ltd

• Website: carcinotech.co.uk
• Ownership type: Venture Capital
• Headquarters: United Kingdom (UK)
• Latest funding: Seed, $5.3M, January 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: carcinotech-ltd

Carcinotech Ltd is a MedTech company based in the United Kingdom, founded in 2018. The company specializes in the development of 3D bioprinted living tumors, utilizing patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Their Carcino3D™ technology provides a platform for rapid and ethical drug discovery, screening, and pre-clinical testing. Carcinotech collaborates with pharmaceutical companies, healthcare professionals, and researchers to enhance treatment outcomes through personalized medicine testing. Recently, the company secured £5.3 million in funding to further develop its innovative technology, highlighting its commitment to improving cancer treatment methodologies.

16. Inventia Life Science

• Website: inventia.life
• Ownership type: Venture Capital
• Headquarters: Alexandria, New South Wales, Australia
• Employee distribution: Australia 78%, United States (USA) 12%, United Kingdom (UK) 4%, Other 5%
• Latest funding: January 2023
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: inventia-life-science

Inventia Life Science, founded in 2013 and based in Alexandria, New South Wales, Australia, is a biomedical research company that specializes in the development of advanced 3D cell models for drug discovery and therapeutic applications. Their flagship RASTRUM™ platform enables researchers to create models that closely mimic human tissue, addressing critical needs in the biomedical and pharmaceutical sectors. The company operates through a combination of research and development, providing products and services that enhance the understanding of diseases and the effectiveness of treatments. Inventia Life Science has established itself as a key player in the bioprinting industry by offering innovative solutions that facilitate the creation of complex tissue architectures, which are vital for accurate disease modeling and drug testing. Their technology has been recognized for its potential to transform research methodologies, particularly in cancer and regenerative medicine.

17. Systemic Bio, a 3D Systems company

• Website: systemic.bio
• Ownership type: Corporate
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $15.0M, September 2022
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: systemic-bio

Systemic Bio, a 3D Systems company based in Houston, Texas, is a biotechnology firm founded in 2022. The company specializes in the development of vascularized organ models made from hydrogels and human cells, aimed at enhancing drug discovery and development processes. Their innovative platform, known as h-VIOS™, allows for the creation of up to 32 vascularized hydrogels in a single plate, which can be customized and perfused with various cell types. This technology provides pharmaceutical companies and researchers with human-relevant data, improving the accuracy of drug testing and safety evaluations. Systemic Bio has received a seed investment of $15 million from 3D Systems, which supports their growth and research initiatives. The company actively participates in industry events, showcasing their advancements in organ modeling and drug testing, thus contributing to the ongoing evolution of bioprinting applications in healthcare.

18. Prellis Biologics

• Website: prellisbio.com
• Ownership type: Venture Capital
• Headquarters: Berkeley, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, March 2025
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: prellis-biologics

Prellis Biologics is a biotechnology firm based in Berkeley, California, founded in 2016. The company specializes in antibody discovery and therapeutic development, utilizing cutting-edge technologies such as artificial intelligence and bioprinting. Their flagship EXIS™ platform leverages human immune diversity to create fully human antibodies, addressing the challenges of drug development. A key aspect of their innovation is the bioprinted lymph node organoid (LNO™), which replicates the complex biology of the human immune system in vitro. This allows for rapid and scalable monoclonal antibody discovery. Prellis has engaged in strategic collaborations with major pharmaceutical companies, including Sanofi and Bristol Myers Squibb, to enhance their therapeutic offerings. In March 2022, they raised $35 million in Series C funding to further advance their technology and accelerate drug discovery processes.

19. 3DBioFibR Inc.

• Website: 3dbiofibr.com
• Ownership type: Venture Capital
• Headquarters: Halifax, Nova Scotia, Canada
• Employee distribution: Canada 100%
• Latest funding: Other (Grant), $1.3M, January 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: 3dbiofibr

3DBioFibR Inc., founded in 2020 and based in Halifax, Nova Scotia, is a biotechnology firm dedicated to the production of collagen fibers and scaffolds for tissue engineering. Utilizing a patented dry-spinning technology, the company has developed CollaFibR™, a product line that closely mimics the properties of natural collagen structures. This technology enables the creation of high-quality, scalable solutions for bioprinting and cell culture, addressing significant needs in regenerative medicine. 3DBioFibR has made strides in the bioprinting sector, launching products that improve the shape fidelity and biological relevance of bioprinted constructs. The company has also secured funding, including a recent $3.52 million round aimed at bringing their collagen fiber products to market. Their commitment to innovation and collaboration, such as partnerships for nerve repair projects, positions them as a relevant player in the bioprinting industry.

20. Nanoscribe

• Website: nanoscribe.com
• Ownership type: Corporate
• Headquarters: Eggenstein-Leopoldshafen, Baden-Württemberg, Germany
• Employee distribution: Germany 89%, China 8%, United States (USA) 3%
• Latest funding: $27.2M, November 2024
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: nanoscribe-gmbh

Nanoscribe, founded in 2007 and based in Eggenstein-Leopoldshafen, Germany, specializes in high-precision additive manufacturing. The company offers advanced 3D printing solutions and materials tailored for applications in microfabrication and bioprinting. Their product lineup includes the Quantum X bio, a high-performance 3D bioprinter designed for life sciences applications. Nanoscribe serves a global clientele, including researchers and companies in the life sciences and photonics sectors, who depend on their cutting-edge technologies for superior quality and speed in their projects. With a workforce of around 75 employees and a commitment to innovation, Nanoscribe invests over 25% of its annual revenue into research and development, ensuring they remain at the forefront of microfabrication technology. The company has also secured significant funding, with the latest round amounting to approximately $27 million in November 2024, indicating strong investor confidence in their growth and potential.

21. xolo

• Website: xolo3d.com
• Ownership type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Employee distribution: Germany 100%
• Latest funding: Series A, $8.5M, February 2023
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: xolo3d

xolo GmbH, based in Berlin, Germany, is a 3D printing technology company founded in 2019. The firm specializes in Xolography, a unique printing method that combines physics and chemistry to create high-resolution structures. This technology is particularly applicable in industries such as biotechnology, MedTech, optics, and dental care. xolo offers products like the Xube² printer, designed for both academic and industrial research, and provides services for bioprinting, medical device production, and optical component fabrication. The company primarily serves businesses and research institutions, showcasing its commitment to advancing medical technologies. In February 2023, xolo secured a Series A funding round, raising over 8.5 million euros, which underscores its growth potential and the confidence investors have in its innovative capabilities.

22. Aprecia Pharmaceuticals

• Website: aprecia.com
• Ownership type: Private Equity
• Headquarters: Mason, Ohio, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Debt), $30.0M, July 2016
• Founded year: 2004
• Headcount: 51-200
• LinkedIn: aprecia-pharmaceuticals

Aprecia Pharmaceuticals, founded in 2004 and based in Mason, Ohio, is a private equity-backed pharmaceutical manufacturer that specializes in advanced additive manufacturing and 3D printing technologies for drug delivery. The company has carved out a niche in the pharmaceutical industry by offering innovative solutions that enhance product offerings and streamline manufacturing processes. Aprecia's commitment to innovation is underscored by its impressive portfolio of 126 granted patents and 52 pending, reflecting its ongoing efforts to push the boundaries of 3D printing technology. The company operates a cGMP compliant facility that has undergone multiple FDA inspections, demonstrating its adherence to high-quality standards. Aprecia's flagship product, Spiritam, is notable for being the first FDA-approved 3D-printed drug, showcasing the potential of 3D printing in creating effective pharmaceutical products. With a focus on precision formulation and comprehensive support throughout the drug development process, Aprecia collaborates with pharmaceutical companies to address complex challenges in drug delivery.

23. ST1 Corp. with an official brand of ARTIPORE

• Website: st-1.co.kr
• Ownership type: Private
• Headquarters: Gimhae-Si, Gyeongsangnam-Do, South Korea
• Employee distribution: South Korea 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: st1-artipore

ST1 Corp., also known by its brand ARTIPORE, is a biotechnology firm based in Gimhae-Si, South Korea, founded in 2016. The company specializes in the development and production of medical devices and biomaterials, with a strong emphasis on regenerative medicine. ST1 Corp. is particularly noted for its innovative solutions in 3D cell culture and human-derived collagen. Their technology integrates electrospinning and 3D bioprinting, allowing them to create advanced scaffolds that replicate the extracellular matrix, which is crucial for tissue engineering and regenerative therapies. The company serves healthcare providers and research institutions, providing them with cutting-edge materials for various medical applications. ST1 Corp. has made significant strides in the bioprinting sector, focusing on products that facilitate the repair and regeneration of damaged tissues and organs. They have also received various certifications, including ISO13485, which underscores their commitment to quality in the medical device industry.

24. EpiBone, Inc.

• Website: epibone.com
• Ownership type: Venture Capital
• Headquarters: Brooklyn, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Convertible note, November 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: epibone

EpiBone, Inc. is a biotechnology firm based in Brooklyn, New York, founded in 2013. The company focuses on tissue engineering and regenerative medicine, specifically developing personalized bone grafts tailored to individual patients. By utilizing the patient's own cells, EpiBone aims to enhance the integration and healing of bone grafts, addressing the limitations of traditional bone replacement methods. Their innovative process involves imaging and stem cell extraction, followed by the design of a custom scaffold and bioreactor to grow the graft. This technology allows for the creation of anatomically precise bone grafts that are alive and capable of remodeling after implantation. EpiBone collaborates with medical professionals to provide advanced solutions for skeletal repair, contributing to the evolving field of personalized medicine.

25. Particle3D

• Website: particle3d.com
• Ownership type: Venture Capital
• Headquarters: Odense, Denmark
• Latest funding: Seed, $3.8M, April 2020
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: particle3d

Particle3D, known as Ossiform, is a medical technology firm based in Odense, Denmark, founded in 2017. The company focuses on creating 3D printed bone implants and scaffolds designed for bone regeneration. Their products are tailored to meet the specific needs of patients, offering resorbable solutions that enhance healing outcomes for those with bone defects. Ossiform's technology utilizes β-tricalcium phosphate to produce bio-integrative implants that support the natural formation of new bone. The company has received funding amounting to approximately $3.8 million in a seed round in April 2020, which underscores investor confidence in their innovative approach. Ossiform is dedicated to redefining bone replacements through research and collaboration with healthcare providers, aiming to make high-quality, personalized bone implants accessible to a broader range of patients.

26. Metatissue

• Website: metatissue.com
• Ownership type: Private
• Headquarters: Portugal
• Employee distribution: Portugal 100%
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: metatissue

Metatissue is a private biotechnology company based in Portugal, founded in 2018. The company specializes in designing and manufacturing human protein-based products tailored for applications in cell culture, tissue regeneration, and disease modeling. Metatissue's innovative solutions cater to researchers and pharmaceutical companies, providing essential materials that enhance drug discovery and tissue engineering processes. They have developed a range of products, including bioactive hydrogels and sponges, which are pivotal for 3D cell culture. Their involvement in various R&D projects, such as TechTissue and PULSE, highlights their commitment to advancing bioprinting technologies and improving the efficacy of drug screening and development. Metatissue operates within a science park, which facilitates collaboration and access to resources that support their growth and innovation in the biotechnology sector.

27. Gelomics

• Website: gelomics.com
• Ownership type: Venture Capital
• Headquarters: Kelvin Grove, Queensland, Australia
• Employee distribution: Australia 100%
• Latest funding: Pre-seed, $2.2M, July 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: gelomics-pty-ltd

Gelomics, founded in 2018 and based in Kelvin Grove, Queensland, Australia, is a biotechnology firm focused on advancing 3D tissue culture systems for biomedical research. The company offers innovative products like the LunaGel™ system, which allows researchers to create physiologically relevant cell culture models quickly and efficiently. Their clientele primarily consists of academic institutions and laboratories engaged in drug discovery and tissue engineering. Gelomics has recently secured $2.2 million in pre-seed funding, indicating investor confidence in their technology and market potential. The LunaGel™ system is particularly noteworthy for its compatibility with various cell types and its application as a bioink in 3D bioprinting, highlighting Gelomics' commitment to enhancing research methodologies in the life sciences.

28. Sciperio Inc

• Website: sciperio.com
• Ownership type: Private
• Headquarters: Orlando, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1996
• Headcount: 11-50
• LinkedIn: sciperio-inc

Sciperio Inc, based in Orlando, Florida, is a private research and development firm founded in 1996. The company specializes in mechanical, electrical, chemical, and biological sciences, providing innovative solutions in bioengineering and next-generation electronics. Sciperio's advanced technologies include biomanufacturing systems and printed electronics, addressing significant challenges in healthcare and manufacturing. Their BioFacture product line showcases their commitment to biomanufacturing, particularly with their voxelized bioreactor designed for efficient cell production. This technology is pivotal for applications such as on-demand blood production and cellular therapies. Sciperio has also made strides in printed electronics, merging 3D printing with electronic functionalities, which enhances their capabilities in creating biologically integrated devices. Their work reflects a transdisciplinary approach, allowing them to innovate across various scientific domains.

Bioprinting Companies Insights: Key Companies

Company	Headquarter	Size	Founded	Ownership
Aspect Biosystems	Vancouver, British Columbia, Canada	51-200	2013	Venture Capital
Advanced Solutions Life Sciences	Louisville, Kentucky, United States (USA)	11-50	2013	Private
Next Big Innovation Labs	Bengaluru, Karnataka, India	11-50	2016	Private
Regemat 3d	Granada, Andalusia, Spain	11-50	2015	Private
Foldink	Frisco, Texas, United States (USA)	1-10	2018	Private
Polbionica	Wilmington, Delaware, United States (USA)	11-50	2019	Private
FluidForm Bio	Waltham, Massachusetts, United States (USA)	11-50	2018	Venture Capital
VoxCell BioInnovation	Victoria, British Columbia, Canada	11-50	2020	Venture Capital
FluidForm	Waltham, Massachusetts, United States (USA)	11-50	2018	Private
Avay Biosciences	Bengaluru, Karnataka, India	11-50	2017	Venture Capital
BioCloner Health	Warsaw, Masovian Voivodeship, Poland	11-50	2001	Private
Rokit Healthcare	Geumcheon, Seoul, South Korea	51-200	2012	Venture Capital
TheWell Bioscience	South Brunswick Township, New Jersey, United States (USA)	11-50	2017	Private
Scire Science	Ernakulam, Kerala, India	11-50	2016	Private
Carcinotech Ltd	United Kingdom (UK)	11-50	2018	Venture Capital
Inventia Life Science	Alexandria, New South Wales, Australia	51-200	2013	Venture Capital
Systemic Bio, a 3D Systems company	Houston, Texas, United States (USA)	11-50	2022	Corporate
Prellis Biologics	Berkeley, California, United States (USA)	11-50	2016	Venture Capital
3DBioFibR Inc.	Halifax, Nova Scotia, Canada	11-50	2020	Venture Capital
Nanoscribe	Eggenstein-Leopoldshafen, Baden-Württemberg, Germany	51-200	2007	Corporate
xolo	Berlin, Berlin, Germany	1-10	2019	Venture Capital
Aprecia Pharmaceuticals	Mason, Ohio, United States (USA)	51-200	2004	Private Equity
ST1 Corp. with an official brand of ARTIPORE	Gimhae-Si, Gyeongsangnam-Do, South Korea	11-50	2016	Private
EpiBone, Inc.	Brooklyn, New York, United States (USA)	11-50	2013	Venture Capital
Particle3D	Odense, Denmark	1-10	2017	Venture Capital
Metatissue	Portugal	1-10	2018	Private
Gelomics	Kelvin Grove, Queensland, Australia	11-50	2018	Venture Capital
Sciperio Inc	Orlando, Florida, United States (USA)	11-50	1996	Private

Want to Find More Bioprinting Companies Companies?

If you want to find more companies that provide innovative solutions like bioinks and tissue models you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!